Hannover, 11 February 2019.

• Important step towards vertical integration

• Sustainable expansion of technology leadership targeted

Syntellix AG has acquired 100 per cent of the shares in MSE Materials Science and Engineering Werkstoffzentrum Clausthal GmbH. The relevant contracts were signed and notarised last week in Hannover. It was only in August 2018 that biomedical technology innovator Syntellix announced the acquisition of a 73% majority stake in materials specialist MSE. The complete takeover of its long-standing production and research partner will enable Syntellix to make its processes even more efficient, to exercise greater direct control of machine capacity and production activity, to integrate its substantial expertise even more closely in the company and thus expand its technology leadership. The globally renowned magnesium experts and former MSE owners Prof. Dr.-Ing. Volkmar Neubert and his son Volkmar-Dirk Neubert will remain with the Syntellix Group and the MSE team in their roles as CEOs. “With the complete takeover of MSE, we were able to strategically strengthen our unique position in bioabsorbable metallic implants for orthopaedics and trauma surgery, and with regard to the planned IPO to also adequately substantiate MSE’s importance in the past and future development of innovative implants made from our MAGNEZIX^®,” says Prof. Dr. Utz Claassen, CEO of Syntellix AG.

With the acquisition of MSE, Syntellix has created an even broader foundation for its ambitious plans. In February, the company will launch a new highly innovative implant system called StarFuse^®.

To expand further internationally, Syntellix has also established new subsidiaries in the Philippines and Brazil to coordinate the development of these high-potential mass markets locally. In addition, preparations for the planned IPO on the Singapore stock exchange are being pursued rigorously and speedily.

About Syntellix: 

Syntellix is an internationally operating medical technology company with headquarters in Hannover, Germany, that is undergoing dynamic growth. The company specialises in the research and development and marketing and sales of highly innovative transformable metallic implants. Products made from the company’s patented MAGNEZIX^® are unique. In a widely acclaimed publication, they were evaluated as being superior clinically to the titanium implants commonly used. The implants break down in the body and are transformed into the body's own bone tissue, and in doing so offer an ideal combination of stability, elasticity and bioabsorbability.

Syntellix is the world's market and technology leader in the field of bioabsorbable metallic orthopaedic implants and has already been honoured with numerous important awards and prizes. In Germany these include the German Business Innovation Award 2012/13, the Future Award 2016 of the German healthcare industry, the German Medical Award 2017, the STEP Award 2017 and the Innovator of the Year 2017 award; internationally the implants were a winner in the Product of the Year category of the Sustainability Award 2018 program.